Article

Johnson & Johnson Vision Care Institute president to retire

Johnson & Johnson (J & J) Vision Care Institute President Phil Keefer has announced his decision to retire Sept. 1 after a 23-year career with the company and more than 40 years in the eye-care industry.

Jacksonville, FL-Johnson & Johnson (J & J) Vision Care Institute President Phil Keefer has announced his decision to retire Sept. 1 after a 23-year career with the company and more than 40 years in the eye-care industry.

Keefer joined J & J’s vision-care division in 1989 as executive vice president of sales, marketing, professional affairs, and strategic planning. In that role, he oversaw the initial launch of a contact lens brand (Acuvue) and helped expand the product line. In 1993, Keefer was appointed vice president of new business development, where he helped expand the vision-care franchise. He served as managing director/president of multiple regions, including Asia Pacific, the Americas, Latin America, and Japan.

In his current role as president of the Vision Care Institute, Keefer helped create 15 vision-care institutes and nine satellite centers around the world. He also has served on the J & J Vision Care Global Management Board the entire time he has worked for the company.

In addition to fulfilling the responsibilities of his positions, Keefer was chairman of the Contact Lens Institute Board of Governors and also served on several boards, including those of the American Optometric Foundation, VisionWeb Inc., the Vision Council of America, and Prevent Blindness America and its Florida organization. In 2009, the American Academy of Optometry presented him with an honorary fellowship for his contributions to the field.

Before joining J & J, Keefer held positions at Allergan, CooperVision, Optical Radiation Corp., and Polymer Technology Corp. At the latter company, he took the company from start-up status to one with global distribution.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.